Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML).

Literature DB >> 26082270

Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML).

A Pigneux^1,2, M Labopin^3,4,5,6, J Maertens⁷, C Cordonnier⁸, L Volin⁹, G Socié¹⁰, D Blaise¹¹, C Craddock¹², N Milpied¹, U Bacher¹³, F Malard^3,4,5,6, J Esteve¹⁴, A Nagler^4,15, M Mohty^3,4,5,6.

Abstract

Acute myeloid leukemia (AML) with 11q23/MLL rearrangement (MLL-r AML) is allocated to the intermediate- or high-risk cytogenetic prognostic category depending on the MLL fusion partner. A more favorable outcome has been reported in patients receiving an allogeneic hematopoietic stem-cell transplantation (alloHSCT), but this has not been confirmed in large series. We analyzed the outcome of alloHSCT among adult patients reported to the Acute Leukemia Working Party between 2000 and 2010. We identified 159 patients with 11q23/MLL rearranged AML allografted in first complete remission (CR1, n=138) or CR2, mostly corresponding to t(9;11), t(11;19), t(6;11) and t(10;11) translocations. Two-year overall survival (OS), leukemia-free survival (LFS), relapse incidence and non-relapse mortality were 56±4%, 51±4%, 31±3% and 17±4%, respectively. The outcome differed according to 11q23/MLL rearrangement, being more favorable in patients with t(9;11) and t(11;19) compared with t(10;11) and t(6;11) (2-year OS: 64±6% and 73±10% vs 40±13% and 24±11%, respectively; P<0.0001). Multivariate analysis for OS identified t(6;11), t(10;11), age>40 years and CR2 as unfavorable features, whereas t(6;11), t(10;11), CR2 and the use of reduced-intensity conditioning regimen affected poorly the LFS. This study confirms the potential role of alloHSCT for adult patients with 11q23/MLL rearranged AML in CR1.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2015 PMID： 26082270 DOI： 10.1038/leu.2015.143

Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528

23 in total

1. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9.

Authors: Paul M Ayton; Michael L Cleary
Journal: Genes Dev Date: 2003-09-02 Impact factor: 11.361

2. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

Authors: Scott R Daigle; Edward J Olhava; Carly A Therkelsen; Aravind Basavapathruni; Lei Jin; P Ann Boriack-Sjodin; Christina J Allain; Christine R Klaus; Alejandra Raimondi; Margaret Porter Scott; Nigel J Waters; Richard Chesworth; Mikel P Moyer; Robert A Copeland; Victoria M Richon; Roy M Pollock
Journal: Blood Date: 2013-06-25 Impact factor: 22.113

3. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

Authors: David Grimwade; Robert K Hills; Anthony V Moorman; Helen Walker; Stephen Chatters; Anthony H Goldstone; Keith Wheatley; Christine J Harrison; Alan K Burnett
Journal: Blood Date: 2010-04-12 Impact factor: 22.113

4. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Authors: A Ferrant; M Labopin; F Frassoni; H G Prentice; J Y Cahn; D Blaise; J Reiffers; G Visani; M A Sanz; M A Boogaerts; B Löwenberg; N C Gorin
Journal: Blood Date: 1997-10-15 Impact factor: 22.113

5. Adult patients with de novo acute myeloid leukemia and t(9; 11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study.

Authors: K Mrózek; K Heinonen; D Lawrence; A J Carroll; P R Koduru; K W Rao; M P Strout; R E Hutchison; J O Moore; R J Mayer; C A Schiffer; C D Bloomfield
Journal: Blood Date: 1997-12-01 Impact factor: 22.113

6. Allogeneic stem cell transplantation for relapsed and refractory acute myeloid leukemia patients with 11q23 abnormalities.

Authors: S M Garrido; E Bryant; F R Appelbaum
Journal: Leuk Res Date: 2000-06 Impact factor: 3.156

Review 7. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Authors: Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Journal: Blood Date: 2009-10-30 Impact factor: 22.113

8. Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup.

Authors: Jürgen Krauter; Katharina Wagner; Irina Schäfer; Rolf Marschalek; Claus Meyer; Gerhard Heil; Markus Schaich; Gerhard Ehninger; Dietger Niederwieser; Rainer Krahl; Thomas Büchner; Cristina Sauerland; Brigitte Schlegelberger; Konstanze Döhner; Hartmut Döhner; Richard F Schlenk; Arnold Ganser
Journal: J Clin Oncol Date: 2009-04-20 Impact factor: 44.544

9. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group.

Authors: Stefan Gröschel; Richard F Schlenk; Jan Engelmann; Veronika Rockova; Veronica Teleanu; Michael W M Kühn; Karina Eiwen; Claudia Erpelinck; Marije Havermans; Michael Lübbert; Ulrich Germing; Ingo G H Schmidt-Wolf; H Berna Beverloo; Gerrit J Schuurhuis; Gert J Ossenkoppele; Brigitte Schlegelberger; Leo F Verdonck; Edo Vellenga; Gregor Verhoef; Peter Vandenberghe; Thomas Pabst; Mario Bargetzi; Jürgen Krauter; Arnold Ganser; Peter J M Valk; Bob Löwenberg; Konstanze Döhner; Hartmut Döhner; Ruud Delwel
Journal: J Clin Oncol Date: 2012-09-24 Impact factor: 44.544

10. The MLL recombinome of acute leukemias in 2013.

Authors: C Meyer; J Hofmann; T Burmeister; D Gröger; T S Park; M Emerenciano; M Pombo de Oliveira; A Renneville; P Villarese; E Macintyre; H Cavé; E Clappier; K Mass-Malo; J Zuna; J Trka; E De Braekeleer; M De Braekeleer; S H Oh; G Tsaur; L Fechina; V H J van der Velden; J J M van Dongen; E Delabesse; R Binato; M L M Silva; A Kustanovich; O Aleinikova; M H Harris; T Lund-Aho; V Juvonen; O Heidenreich; J Vormoor; W W L Choi; M Jarosova; A Kolenova; C Bueno; P Menendez; S Wehner; C Eckert; P Talmant; S Tondeur; E Lippert; E Launay; C Henry; P Ballerini; H Lapillone; M B Callanan; J M Cayuela; C Herbaux; G Cazzaniga; P M Kakadiya; S Bohlander; M Ahlmann; J R Choi; P Gameiro; D S Lee; J Krauter; P Cornillet-Lefebvre; G Te Kronnie; B W Schäfer; S Kubetzko; C N Alonso; U zur Stadt; R Sutton; N C Venn; S Izraeli; L Trakhtenbrot; H O Madsen; P Archer; J Hancock; N Cerveira; M R Teixeira; L Lo Nigro; A Möricke; M Stanulla; M Schrappe; L Sedék; T Szczepański; C M Zwaan; E A Coenen; M M van den Heuvel-Eibrink; S Strehl; M Dworzak; R Panzer-Grümayer; T Dingermann; T Klingebiel; R Marschalek
Journal: Leukemia Date: 2013-04-30 Impact factor: 11.528

17 in total

1. Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation.

Authors: F-X Gros; T Cazaubiel; E Forcade; N Lechevalier; T Leguay; V Servant; R Tabrizi; L Clement; P-Y Dumas; A Bidet; A Pigneux; S Vigouroux; N Milpied
Journal: Bone Marrow Transplant Date: 2017-06-05 Impact factor: 5.483

Review 2. The who, how and why: Allogeneic transplant for acute myeloid leukemia in patients older than 60years.

Authors: Sarah A Wall; Steven Devine; Sumithira Vasu
Journal: Blood Rev Date: 2017-07-15 Impact factor: 8.250

3. Therapeutic Targeting of MLL Degradation Pathways in MLL-Rearranged Leukemia.

Authors: Kaiwei Liang; Andrew G Volk; Jeffrey S Haug; Stacy A Marshall; Ashley R Woodfin; Elizabeth T Bartom; Joshua M Gilmore; Laurence Florens; Michael P Washburn; Kelly D Sullivan; Joaquin M Espinosa; Joseph Cannova; Jiwang Zhang; Edwin R Smith; John D Crispino; Ali Shilatifard
Journal: Cell Date: 2017-01-05 Impact factor: 41.582

Review 4. The molecular mechanics of mixed lineage leukemia.

Authors: R K Slany
Journal: Oncogene Date: 2016-02-29 Impact factor: 9.867

5. Minimal residual disease monitoring and preemptive immunotherapies for frequent 11q23 rearranged acute leukemia after allogeneic hematopoietic stem cell transplantation.

Authors: Jing Liu; Xiao-Hui Zhang; Lan-Ping Xu; Yu Wang; Chen-Hua Yan; Huan Chen; Yu-Hong Chen; Wei Han; Feng-Rong Wang; Jing-Zhi Wang; Yi-Fei Cheng; Ya-Zhen Qin; Kai-Yan Liu; Xiao-Jun Huang; Xiao-Su Zhao; Xiao-Dong Mo
Journal: Ann Hematol Date: 2021-03-13 Impact factor: 3.673

6. The role of EVI1 gene quantification in AML patients with 11q23/MLL rearrangement after allogeneic hematopoietic stem cell transplantation.

Authors: Shuhui Jiang; Yi Fan; Yanglan Fang; Chang Hou; Jia Chen; Jiannong Cen; Huiying Qiu; Suning Chen; Yang Xu; Depei Wu
Journal: Bone Marrow Transplant Date: 2020-09-05 Impact factor: 5.483